Advanced Enzyme Technologies (ADVENZYMES) Panoramica del titolo
Advanced Enzyme Technologies Limited, insieme alle sue controllate, si occupa di ricerca, sviluppo, produzione e commercializzazione di enzimi e probiotici in India, Europa, Stati Uniti, Asia e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 5/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 4/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per ADVENZYMES dai nostri controlli di rischio.
ADVENZYMES Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Advanced Enzyme Technologies Limited
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | ₹317.60 |
| Massimo di 52 settimane | ₹419.00 |
| Minimo di 52 settimane | ₹251.95 |
| Beta | 0.69 |
| Variazione di 1 mese | -13.47% |
| Variazione a 3 mesi | 13.92% |
| Variazione di 1 anno | -6.11% |
| Variazione a 3 anni | 11.93% |
| Variazione a 5 anni | -21.36% |
| Variazione dall'IPO | 15.48% |
Notizie e aggiornamenti recenti
Articolo di analisi • Jun 30
If EPS Growth Is Important To You, Advanced Enzyme Technologies (NSE:ADVENZYMES) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Aggiornamento della narrazione • Jun 18
ADVENZYMES: Stable Case Balances Model Assumptions And Upcoming Dividend Decisions
Analysts have kept their ₹370 price target on Advanced Enzyme Technologies unchanged, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E that, in their view, broadly offset each other in the valuation model. Analyst Commentary Recent commentary on Advanced Enzyme Technologies highlights a mix of optimism about the company’s positioning and caution around execution and valuation assumptions, which feeds into how analysts are thinking about the ₹370 target.Aggiornamento della narrazione • Jun 01
ADVENZYMES: Steady Cash Assumptions And Upcoming Board Decisions Will Shape Returns
Narrative update on Advanced Enzyme Technologies The analyst price target for Advanced Enzyme Technologies is held steady at ₹370, as analysts point to only very small adjustments in assumptions for discount rate, revenue growth, profit margin and forward P/E after reviewing recent research on comparable companies. Analyst Commentary Recent Street research on other mid-cap service companies has given analysts a reference point as they revisit models for Advanced Enzyme Technologies, even though those reports focus on a different stock.Recent updates
Articolo di analisi • Jun 30
If EPS Growth Is Important To You, Advanced Enzyme Technologies (NSE:ADVENZYMES) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Aggiornamento della narrazione • Jun 18
ADVENZYMES: Stable Case Balances Model Assumptions And Upcoming Dividend Decisions
Analysts have kept their ₹370 price target on Advanced Enzyme Technologies unchanged, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E that, in their view, broadly offset each other in the valuation model. Analyst Commentary Recent commentary on Advanced Enzyme Technologies highlights a mix of optimism about the company’s positioning and caution around execution and valuation assumptions, which feeds into how analysts are thinking about the ₹370 target.Aggiornamento della narrazione • Jun 01
ADVENZYMES: Steady Cash Assumptions And Upcoming Board Decisions Will Shape Returns
Narrative update on Advanced Enzyme Technologies The analyst price target for Advanced Enzyme Technologies is held steady at ₹370, as analysts point to only very small adjustments in assumptions for discount rate, revenue growth, profit margin and forward P/E after reviewing recent research on comparable companies. Analyst Commentary Recent Street research on other mid-cap service companies has given analysts a reference point as they revisit models for Advanced Enzyme Technologies, even though those reports focus on a different stock.Aggiornamento della narrazione • May 12
ADVENZYMES: Stable Margins And Refined Assumptions Will Guide Future Returns
Analysts kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, citing modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions rather than any change in their core outlook. Analyst Commentary Analysts keeping fair value at ₹370 are focusing on how well Advanced Enzyme Technologies can execute on its current plan rather than changing their fundamental view of the stock.Aggiornamento della narrazione • Apr 19
ADVENZYMES: Steady Risk And Margins Will Support Future Upside
Analysts have kept their fair value estimate for Advanced Enzyme Technologies steady at ₹370. They cited updated assumptions around the discount rate, growth, margins and future P/E that reflect fine tuning of their models rather than a change in overall conviction.Aggiornamento della narrazione • Apr 05
ADVENZYMES: Steady Assumptions And Risk Profile Will Support Future Upside
Analysts have kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, with only small adjustments to the discount rate, growth, margin and future P/E assumptions informing this unchanged price target. Analyst Commentary Bullish Takeaways Bullish analysts see support for the ₹370 fair value estimate from the decision to keep key model assumptions, such as growth and margins, broadly consistent rather than revising them sharply.Aggiornamento della narrazione • Mar 21
ADVENZYMES: Refined Risk Assumptions And Stable Outlook Will Support Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370, making small changes to assumptions such as a slightly lower discount rate and marginally adjusted long-term growth and P/E inputs after revisiting their models. Analyst Commentary Bullish Takeaways Bullish analysts see the reaffirmed fair value of ₹370 as supported by refreshed assumptions, suggesting that the refined discount rate and long term inputs still back the existing valuation framework for Advanced Enzyme Technologies.Aggiornamento della narrazione • Mar 06
ADVENZYMES: Free Cash Flow Momentum And Cleaner Portfolio Will Drive Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370.0 per share, while slightly adjusting assumptions on discount rate, growth, margins and future P/E to reflect updated free cash flow trends and a cleaner portfolio. They expect these factors to support improvement in the second half.Aggiornamento della narrazione • Feb 20
ADVENZYMES: Stable Assumptions And Future P/E Reset Will Drive Upside
Analysts have kept their price target for Advanced Enzyme Technologies steady at ₹370, citing largely unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E in their updated models. What's in the News A board meeting is scheduled on January 31, 2026 to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Aggiornamento della narrazione • Feb 05
ADVENZYMES: Future P/E Reset Will Signal Upside Potential For Shares
Analysts have trimmed their fair value estimate for Advanced Enzyme Technologies from ₹440 to ₹370, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower future P/E multiple. What's in the News Board meeting scheduled for January 31, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Articolo di analisi • Jan 31
Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price Not Quite Adding Up
There wouldn't be many who think Advanced Enzyme Technologies Limited's ( NSE:ADVENZYMES ) price-to-earnings (or "P/E...Nuova narrazione • Aug 17
Preventive Health And Green Chemistry Will Expand Future Markets
Key Takeaways Expansion into health, wellness, and sustainable enzymatic solutions, along with new B2C initiatives, positions for growth and improved margins as consumer demand rises. International diversification, R&D investment, and increased capacity utilization support long-term product differentiation, earnings stability, and operating leverage.Articolo di analisi • Aug 04
Here's What's Concerning About Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Articolo di analisi • Jun 27
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...Articolo di analisi • Jun 12
Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...Articolo di analisi • Mar 25
Is Advanced Enzyme Technologies (NSE:ADVENZYMES) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Aug 20
After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar
Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) shareholders have had their patience rewarded with a 26% share...Articolo di analisi • Jul 19
We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now
Key Insights Advanced Enzyme Technologies' Annual General Meeting to take place on 25th of July Salary of ₹6.69m is...Articolo di analisi • Jul 13
Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.00...Articolo di analisi • Apr 08
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Articolo di analisi • Sep 23
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Articolo di analisi • Feb 03
Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...Articolo di analisi • Aug 11
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Rendimenti per gli azionisti
| ADVENZYMES | IN Chemicals | IN Mercato | |
|---|---|---|---|
| 7D | -8.8% | 1.9% | 1.0% |
| 1Y | -6.1% | -4.7% | -1.4% |
Ritorno vs Industria: ADVENZYMES ha avuto una performance inferiore rispetto al Indian Chemicals che ha registrato un rendimento -4.7 % nell'ultimo anno.
Rendimento vs Mercato: ADVENZYMES ha avuto una performance inferiore al mercato Indian che ha registrato un rendimento -1.4 % nell'ultimo anno.
Volatilità dei prezzi
| ADVENZYMES volatility | |
|---|---|
| ADVENZYMES Average Weekly Movement | 6.6% |
| Chemicals Industry Average Movement | 6.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.1% |
Prezzo delle azioni stabile: ADVENZYMES non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Indian.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di ADVENZYMES è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1957 | 338 | n/a | www.advancedenzymes.com |
Advanced Enzyme Technologies Limited, insieme alle sue controllate, si occupa di ricerca, sviluppo, produzione e commercializzazione di enzimi e probiotici in India, Europa, Stati Uniti, Asia e a livello internazionale. L'azienda offre enzimi e integratori alimentari a base di probiotici per la salute umana e l'alimentazione animale, la lavorazione di frutta e verdura, la panificazione, la produzione di birra e malto, la lavorazione di amido e cereali, la modificazione delle proteine, la lavorazione del lievito, la lavorazione di latticini e formaggi, la lavorazione di oli e grassi, nonché per applicazioni speciali, biocarburanti e biocatalisi. Fornisce enzimi per la lavorazione di prodotti non alimentari per il settore tessile, del cuoio, della pasta di legno e della carta, nonché detergenti e coadiuvanti per la pulizia.
Advanced Enzyme Technologies Limited Riepilogo dei fondamenti
| ADVENZYMES statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | ₹35.56b |
| Utili (TTM) | ₹1.69b |
| Ricavi(TTM) | ₹7.46b |
21.1x
Rapporto P/E4.8x
Rapporto P/SADVENZYMES è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ADVENZYMES Conto economico (TTM) | |
|---|---|
| Ricavi | ₹7.46b |
| Costo del fatturato | ₹1.93b |
| Profitto lordo | ₹5.53b |
| Altre spese | ₹3.84b |
| Utili | ₹1.69b |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 15.07 |
| Margine lordo | 74.13% |
| Margine di profitto netto | 22.62% |
| Rapporto debito/patrimonio netto | 1.2% |
Come si è comportato ADVENZYMES nel lungo periodo?
Vedi performance storica e confrontoDividendi
1.7%
Rendimento attuale del dividendo35%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/05 18:40 |
| Prezzo dell'azione a fine giornata | 2026/07/03 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Advanced Enzyme Technologies Limited è coperta da 4 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Nandan Chakraborty | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| null null | DBS Bank Ltd |